Neopharm’s colon-cancer drug falls short
WAUKEGAN, Ill., March 30 (UPI) — Neopharm's experimental treatment for metastatic colorectal cancer, LE-SN38, missed its mark in a Phase 2 study, the company said late Friday. Neopharm had been testing the drug as a second-line therapy for metastatic colorectal cancer.
The drug maker said an interim analysis of data following treatment of the first 21 patients enrolled in the trial showed “disease stabilization,” but
added the investigational treatment still failed to achieve its primary tumor-response endpoint.
Neopharm said no new patients would be enrolled into the study — conducted by the Cancer and Leukemia Group B, a clinical research group sponsored by the National Cancer Institute — but added that patients already receiving therapy would continue treatment until a study endpoint is reached.
The company said its next steps could include more data analyses and possibly additional studies.
LE-SN38 is the active metabolite of Pfizer's cancer drug Camptosar.
